



Xcopri in India

The CDSCO named-patient coordination pathway — indicative 2026

NEUROLOGY · DRUG-RESISTANT FOCAL EPILEPSY

The clinical situation

Xcopri (cenobamate) is an FDA-approved oral anti-seizure medicine for partial-onset (focal) seizures in adults, manufactured by SK Life Science. It is typically considered after failure of two or more conventional ASMs. Dosing starts at 12.5 mg with slow titration every two weeks to a target maintenance dose of 200 mg daily (max 400 mg). Slow titration is critical: Xcopri carries a US warning for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and QT-shortening considerations in patients with family short-QT syndrome. Your treating epileptologist confirms drug-resistant focal epilepsy per ILAE criteria and sets the titration plan.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Drug-resistant focal epilepsy diagnosis, prior ASM trial documentation, and titration plan.
- 2 CDSCO personal-use application.** Physician or importing pharmacy files clinical rationale, patient reference, dosing plan, and chain-of-custody.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 4 Shipment.** Xcopri ships at controlled room temperature; no cold-chain is required.
- 5 Arrival & titration start.** Your epileptologist initiates and supervises slow titration across ~11 weeks to maintenance.

Indicative economics

Reference US cash-pay range: USD 700–1,000 per month at maintenance dose (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review, keyed to the drug-resistant focal epilepsy rationale. **Logistics.** Room-temperature shipment coordination. **Concierge case lead.** Named point of contact for multi-month titration supply. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating epileptologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Xcopri × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/xcopri-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team